Back to Search Start Over

Subchondral bone osteoclasts induce sensory innervation and osteoarthritis pain

Authors :
Zhu, Shouan
Zhu, Jianxi
Zhen, Gehua
Hu, Yihe
An, Senbo
Li, Yusheng
Zheng, Qin
Chen, Zhiyong
Yang, Ya
Wan, Mei
Skolasky, Richard Leroy
Cao, Yong
Wu, Tianding
Gao, Bo
Yang, Mi
Gao, Manman
Kuliwaba, Julia
Ni, Shuangfei
Wang, Lei
Wu, Chuanlong
Findlay, David
Eltzschig, Holger K.
Ouyang, Hong Wei
Crane, Janet
Zhou, Feng-Quan
Guan, Yun
Dong, Xinzhong
Cao, Xu
Source :
Journal of Clinical Investigation. March, 2019, Vol. 129 Issue 3, p1076, 18 p.
Publication Year :
2019

Abstract

Joint pain is the defining symptom of osteoarthritis (OA) but its origin and mechanisms remain unclear. Here, we investigated an unprecedented role of osteoclast-initiated subchondral bone remodeling in sensory innervation for OA pain. We show that osteoclasts secrete netrin-1 to induce sensory nerve axonal growth in subchondral bone. Reduction of osteoclast formation by knockout of receptor activator of nuclear factor kappa-B ligand (Rank!) in osteocytes inhibited the growth of sensory nerves into subchondral bone, dorsal root ganglion neuron hyperexcitability, and behavioral measures of pain hypersensitivity in OA mice. Moreover, we demonstrated a possible role for netrin-1 secreted by osteoclasts during aberrant subchondral bone remodeling in inducing sensory innervation and OA pain through its receptor DCC (deleted in colorectal cancer). Importantly, knockout of Netrin1 in tartrate-resistant acid phosphatase-positive (TRAP- positive) osteoclasts or knockdown of Dcc reduces OA pain behavior. In particular, inhibition of osteoclast activity by alendronate modifies aberrant subchondral bone remodeling and reduces innervation and pain behavior at the early stage of OA. These results suggest that intervention of the axonal guidance molecules (e.g., netrin-1) derived from aberrant subchondral bone remodeling may have therapeutic potential for OA pain.<br />Introduction Osteoarthritis (OA) is a common musculoskeletal disease in adults, and it is estimated that it will affect 78 million people by 2040 (1), leading to disability and reduced quality [...]

Details

Language :
English
ISSN :
00219738
Volume :
129
Issue :
3
Database :
Gale General OneFile
Journal :
Journal of Clinical Investigation
Publication Type :
Academic Journal
Accession number :
edsgcl.577907795
Full Text :
https://doi.org/10.1172/JC121561